Important Notice
The appropriate dose and treatment schedule must be determined by a qualified healthcare professional.
Enzalutamide is a prescription anticancer medicine. The information on this page is an educational overview and should not be used to determine an individual’s dose.
Standard Reference Dose
Current European product information for Xtandi describes a recommended adult dose of 160 mg once daily. This can be administered as four 40 mg tablets or two 80 mg tablets.
The website’s supplied product is Enzamide 40 mg — Everest Pharmaceuticals Ltd..
The fact that a product has a 40 mg strength does not mean that every patient should take a particular number of tablets. The prescribed dose must come from the treating healthcare professional.
Product Strength
The supplied product information identifies:
| Product | Generic | Strength | Company |
|---|---|---|---|
| Enzamide | Enzalutamide | 40 mg | Everest |
The 40 mg figure describes the amount of active ingredient in an individual dosage unit when confirmed by the product labeling.
How Often Is Enzalutamide Taken?
Reference product information describes enzalutamide as a once-daily oral treatment.
Taking the medicine consistently at approximately the same time each day can help maintain a regular treatment routine.
Patients should follow their own prescription rather than using a website to calculate treatment.
With or Without Food
Current reference product information permits administration with or without food.
Patients should follow the instructions supplied with their specific product and prescription.
Swallowing the Medicine
Dosage-form instructions depend on the product.
If the product is supplied as a tablet, it should be administered according to its official labeling.
Patients should not crush, chew, dissolve or otherwise alter a dosage form unless the applicable product information specifically permits that method.
Missed Dose
If a dose is forgotten, patients should follow the instructions provided by their treating healthcare professional or the applicable official product information.
They should not automatically take extra medicine to compensate for a missed dose.
Because specific missed-dose instructions can vary according to the product information and clinical circumstances, professional advice is appropriate when there is uncertainty.
Dose Adjustments
Dose modifications may sometimes be necessary because of adverse reactions, drug interactions or other clinical considerations.
Patients should never reduce or increase enzalutamide themselves.
A physician may determine that treatment should be:
- Continued at the prescribed dose
- Temporarily interrupted
- Adjusted
- Discontinued
depending on the clinical situation.
Drug Interactions and Dosage
Enzalutamide has clinically significant interaction potential.
Some medicines can alter enzalutamide exposure, while enzalutamide can substantially alter the exposure of other medicines.
Therefore, medication review is important before and during treatment.
Special Clinical Considerations
The treating physician may consider individual factors such as:
- Previous seizures
- Neurological disease
- Cardiovascular disease
- Ischemic heart disease
- Other cancer treatments
- Concomitant medications
- Frailty
- Fall risk
- Bone health
- Treatment response
These considerations may affect the overall treatment plan.
Treatment Consistency
Patients receiving enzalutamide should maintain regular communication with their healthcare team.
Treatment should not be stopped simply because symptoms improve or because a patient feels well.
Likewise, side effects should not automatically lead to permanent discontinuation without professional assessment.
Monitoring
Depending on the treatment setting, clinicians may monitor:
- PSA
- Disease progression
- Symptoms
- Blood pressure
- Cardiovascular health
- Neurological symptoms
- Falls
- Bone health
- Drug interactions
- Treatment tolerability
Important Safety Warning
Enzalutamide has been associated with seizures. Patients with a history or increased risk of seizures should discuss this with their healthcare professional before treatment.
Ischemic heart disease is also an identified safety consideration.
Patients should promptly report concerning neurological or cardiovascular symptoms.
Pregnancy Considerations
Enzalutamide is intended for prostate-cancer treatment in men.
The applicable product information contains reproductive and pregnancy precautions. Patients should follow the current official product information and advice from their healthcare professional concerning contraception and reproductive safety.
Never Self-Medicate
Online information cannot determine:
- The correct dose
- Treatment duration
- Whether enzalutamide should be combined with another medicine
- Whether treatment should be interrupted
- Whether a side effect requires dose modification
Those decisions require clinical assessment.
Enzalutamide is generally administered orally once daily in the reference product information. A 40 mg dosage unit is one available strength, and the reference product’s adult recommended dose is 160 mg once daily.
However, the appropriate dose and treatment schedule must be determined by a qualified healthcare professional.